Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice
Open Access
- 29 April 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0237830
Abstract
Regulation of the anti-apoptotic BCL2 protein determines cell survival and is frequently abnormal in B cell lymphomas. An evolutionarily conserved post-translational mechanism for over-expression of BCL2 in human B cell lymphomas and the BCL2 paralogue CED-9 in Caenorhabditis elegans results from loss-of-function mutations in human FBXO10 and its C.elegans paralogue DRE-1, a BCL2/CED-9-binding subunit of the SKP-CULLIN-FBOX (SCF) ubiquitin ligase. Here, we tested the role of FBXO10 in BCL2 regulation by producing mice with two different CRISPR/Cas9-engineered Fbxo10 mutations: an Asp54Lys (E54K) missense mutation in the FBOX domain and a Cys55SerfsTer55 frameshift (fs) truncating mutation. Mice homozygous for either mutant allele were born at the expected Mendelian frequency and appeared normal in body weight and appearance as adults. Spleen B cells from homozygous mutant mice did not have increased BCL2 protein, nor were the numbers of mature B cells or germinal centre B cells increased as would be expected if BCL2 was increased. Other lymphocyte subsets that are also regulated by BCL2 levels also displayed no difference in frequency in homozygous Fbxo10 mutant mice. These results support one of two conclusions: either FBXO10 does not regulate BCL2 in mice, or it does so redundantly with other ubiquitin ligase complexes. Possible candidates for the latter include FBXO11 or ARTS-XIAP. The difference between the role of FBXO10 in regulating BCL2 protein levels in C. elegans and in human DLBCL, relative to single-gene deficient mouse leukocytes, should be further investigated.Keywords
All Related Versions
Funding Information
- National Health and Medical Research Council (APP1113904)
- National Health and Medical Research Council (APP1081858)
- National Health and Medical Research Council (APP1108800)
This publication has 49 references indexed in Scilit:
- Sporadic autism exomes reveal a highly interconnected protein network of de novo mutationsNature, 2012
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencingProceedings of the National Academy of Sciences, 2012
- FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomasNature, 2012
- Sept4/ARTS is required for stem cell apoptosis and tumor suppressionGenes & Development, 2010
- BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphomaProceedings of the National Academy of Sciences, 2009
- The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCLBlood, 2009
- Expression in Non-Hodgkin's Lymphoma of thebcl-2 Protein Associated with the t(14;18) Chromosomal TranslocationNew England Journal of Medicine, 1988
- Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocationCell, 1986
- Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18Cell, 1985
- Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1982